 |
DDW 2008: Biologic Therapy for Inflammatory Bowel Disease -- What Do the Latest Data Say? CME Author Information and Disclosures Release Date: June 23, 2008; Valid for credit through June 23, 2009 | Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of Digestive Disease Week. These materials and the related activity are not sanctioned by Digestive Disease Week or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Assess strategies in biologic therapy for IBD, with emphasis on anti-tumor necrosis factor (TNF)-alpha therapies, on the basis of new data presented at DDW 2008
- Identify ongoing challenges in the management of patients with IBD with the current therapeutic
arsenal, including issues in safety/tolerability
- Review the latest data on the benefits of biologic therapies in IBD beyond clinical response and remission, including avoidance of hospitalizations and surgery and steroid withdrawal
Authors and Disclosures Stephen B. Hanauer, MD, FACG
Disclosure: Stephen B. Hanauer, MD,
FACG, has disclosed that he has received grants for clinical research and educational activities from, and has served as an advisor or consultant to, Shire, Procter & Gamble, Salix, Abbott, Centocor, UCB, and Prometheus. Uma Mahadevan-Velayos, MD
Disclosure: Uma Mahadevan-Velayos, MD, has disclosed that she has served as a consultant to UCB, Abbott, Elan, Centocor, Procter & Gamble, and
Shire. Remo Panaccione, MD, FRCPC
Disclosure: Remo Panaccione, MD, FRCPC, has disclosed that he has served on the speaker's bureau of and/or as a consultant to AstraZeneca, Abbott Laboratories, Byk/Solvay, Janssen-Ortho, Schering Plough, Centocor, Elan, and Prometheus; as a consultant to Ferring, Shire, GlaxoSmithKline, UCB, Procter & Gamble, and Bristol-Myers Squibb; on the advisory board of Ferring, Abbott
Laboratories, Schering-Plough, Shire, Elan, UCB, and Procter & Gamble; received speaker honoraria from Axcan, Shire, and Procter & Gamble; received research and/or educational support from Abbott Laboratories, Schering-Plough, Centocor, Millennium Pharmaceuticals, Elan, Procter & Gamble, and Bristol-Myers Squibb; received educational support from Ferring and Axcan; and received educational honoraria from Janssen and Ferring. Maria
Gaiso
Disclosure: Maria Gaiso has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
